Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030955
Abstract: Simple Summary Cardiotoxicity is a known adverse effect of Carfilzomib therapy; nevertheless, limited data are available on the comparison of the cardiovascular complications induced by Carfilzomib-dexamethasone versus Carfilzomib-lenalidomide-dexamethasone in patients with multiple myeloma (MM) in… read more here.
Keywords: carfilzomib; dexamethasone; incidence; carfilzomib dexamethasone ... See more keywords